New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2013
08:42 EDTCCXIChemoCentryx completes target enrollment of CCX140 Phase II trial
ChemoCentryx announced that it has completed the target enrollment of 270 patients in a Phase II clinical trial in diabetic nephropathy with CCX140, an inhibitor of the chemokine receptor known as CCR2 and the Company's lead wholly owned drug candidate. Enrollment will be closed by June 30, 2013, at which time ChemoCentryx expects total enrollment to exceed 300 patients in the randomized, double-blind, placebo-controlled study.
News For CCXI From The Last 14 Days
Check below for free stories on CCXI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for CCXI

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use